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Abstract
The expression of focal adhesion kinase family interacting protein of 200-kDa (FIP200) in normal brain is limited to some
neurons and glial cells. On immunohistochemical analysis of biopsies of glioblastoma tumors, we detected FIP200 in the
tumor cells, tumor-associated endothelial cells, and occasional glial cells. Human glioblastoma tumor cell lines and
immortalized human astrocytes cultured in complete media also expressed FIP200 as did primary human brain microvessel
endothelial cells (MvEC), which proliferate in culture and resemble reactive endothelial cells. Downregulation of
endogenous expression of FIP200 using small interfering RNA resulted in induction of apoptosis in the human glioblastoma
tumor cells, immortalized human astrocytes, and primary human brain MvEC. It has been shown by other investigators
using cells from other tissues that FIP200 can interact directly with, and inhibit, proline-rich tyrosine kinase 2 (Pyk2) and
focal adhesion kinase (FAK). In the human glioblastoma tumor cells, immortalized human astrocytes, and primary human
brain MvEC, we found that downregulation of FIP200 increased the activity of Pyk2 without increasing its expression, but
did not affect the activity or expression of FAK. Coimmunoprecipitation and colocalization studies indicated that the
endogenous FIP200 was largely associated with Pyk2, rather than FAK, in the glioblastoma tumor cells and brain MvEC.
Moreover, the pro-apoptotic effect of FIP200 downregulation was inhibited significantly by a TAT-Pyk2-fusion protein
containing the Pyk2 autophosphorylation site in these cells. In summary, downregulation of endogenous FIP200 protein in
glioblastoma tumor cells, astrocytes, and brain MvECs promotes apoptosis, most likely due to the removal of a direct
interaction of FIP200 with Pyk2 that inhibits Pyk2 activation, suggesting that FIP200 expression may be required for the
survival of all three cell types found in glioblastoma tumors.
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Introduction
The focal adhesion kinase family interacting protein of 200-kDa
(FIP200), which is also known as retinoblastoma coiled coil protein
1 (Rb1CC1), can interact with and regulate the activity of several
different proteins that are involved in the signaling of proliferation,
apoptosis, autophagy, and cell cycle progression [1–4] and is
therefore particularly well-positioned to regulate cell survival. The
FIP200-nullizygous state is embryonic lethal in mice and E14.5–
E15.5 day embryos show histologic evidence of heart failure and
liver degeneration that is associated with high levels of apoptosis in
the heart and liver tissue [5]. The FIP200 gene is highly conserved
and is expressed in a wide variety of tissues and cell lines [2,6];
however, its effects appear to be highly dependent on the cell type
and the experimental conditions [3].
Several different regulatory mechanisms have been identified
that may affect FIP200 activity, including its level of expression
[7], localization (cytoplasmic vs. nuclear) [1,3,8–10], and its
interaction with other proteins [3,4,10]. FIP200 can interact
directly with the kinase domains of both focal adhesion kinase
(FAK) and proline-rich tyrosine kinase 2 (Pyk2, also known as
related adhesion focal tyrosine kinase, calcium-dependent tyrosine
kinase, and focal adhesion kinase-2). Overexpression of FIP200
inhibits the kinase activity and the kinase-associated cellular
PLoS ONE | www.plosone.org 1 May 2011 | Volume 6 | Issue 5 | e19629functions of these proteins [1,2]. Both Pyk2 and FAK regulate cell
proliferation, apoptosis, and the cell cycle; in general, Pyk2 acts to
downregulate cell survival whereas FAK acts to promote it
[11–17]. The forced overexpression of Pyk2 induces apoptosis,
with the N-terminal and kinase domains of Pyk2 being necessary
for this effect [11,18]. Some apoptosis signals [12,19] activate Pyk2
including TNFa [19]. Clues to the associated signaling pathways
are provided by the findings that methylmethane sulfonate
induction of apoptosis requires Pyk2 activation of JNK [20] and
expression of the transcription factor Smad4 can increase Pyk2
expression with a subsequent promotion of apoptosis in MDA-
MB468 cells [21].
Evidence that Pyk2 can modulate FAK activity has been
generated through analysis of FAK-mediated promotion of cell
cycle progression. FAK can promote cell cycle progression
through activation of ERK and induction of the transcription
factor Kruppel-like factor 8 (KLF8), which activates transcription
of cyclin D1, as well as through inhibition of p27(Kip1) expression
in glioblastoma cells [13–15,17]. The C-terminal domain of Pyk2
is necessary for its inhibition of the cell cycle [13] and expression of
Pyk2 in cells with a low level of endogenous Pyk2 inhibits cell cycle
progression through the differential activation of JNK and ERK
[13]. Notably, Pyk2 also can inhibit cell cycle progression by
competing with endogenous FAK for binding partners. Specifi-
cally, Pyk2 can effectively compete with FAK for binding to Src
and/or Fyn and thereby inhibit ERK activation [13].
The analysis ofthe potential roleof FIP200 intumor development
has focused, for the most part, on breast cancer [7,22,23], and there
has been one report of the effects of transient downregulation of
FIP200 in breast tumor cells [7]. We investigated whether
endogenous FIP200 protein regulates the proliferation of cells found
in glioblastoma tumors and whether it does so by regulating Pyk2
and/or FAK activity. We and others have shown previously that
Pyk2 and FAK can regulate cell proliferation and survival in
glioblastoma cells, with overexpression of Pyk2 decreasing and
overexpression of FAK enhancing cell proliferation [17,24,25]. In
the current studies, we found that FIP200 is expressed in tumor cells
and occasional glial cells in glioblastoma tumor biopsies. It also was
present in the endothelial cells in the tumor-associated vessels,
although it is not detectable in the endothelial cells in the vessels of
normal brain. siRNAdownregulation of endogenousFIP200protein
inhibited cell proliferation and induced apoptosis in U-87MG
human glioblastoma cells, immortalized human astrocytes, and
human brain microvessel endothelial cells (MvECs) propagated in
complete media, which are reactive and commonly used as a
surrogate model of tumor-associated MvECs. FIP200 downregula-
tionincreasedPyk2activity,withoutaffectingFAKactivity.Thepro-
apoptotic effect was blocked by a fusion protein containing the Pyk2
autophosphorylation site in the glioblastoma cells and the MvECs.
This preferential effect of the FIP200 downregulation on Pyk2
activity may be explained by the greater association of FIP200 with
Pyk2, rather than FAK. Our data suggest that FIP200 may be
necessary for the survival of multiple cell types found in glioblastoma
tumors, and that FIP200 inhibition of Pyk2 activity may play a
prominent role in this promotion of survival.
Results
FIP200 Protein is Expressed in Tumor Cells, Glial Cells and
the Endothelial Cells of Tumor-Associated Vessels in
Glioblastoma Biopsies
Immunohistochemical analysis of the expression of FIP200 in
formalin-fixed, paraffin-embedded biopsies was carried out using a
rabbit anti-FIP200 antibody used previously to identify FIP200
expression in neurons in the brain [10]. Representative photomi-
crographs are shown in Figure 1. In all of the 20 normal brain
biopsies, FIP200 was detected in the cytoplasm of a population of
neurons (Figure 1B) and in the cytoplasm of occasional glial cells
(data not shown); with the FIP200 being largely localized to the
cortex. The detection of FIP200 in a population of neurons in the
normal brain cortex is consistent with its reported role in
maintaining normal homeostasis of neurons [10]. In the tumor
biopsies from 14 of 21 patients with glioblastoma, FIP200 was
detectable in the tumor cells. As can be seen in the representative
photomicrographs shown in Figure 1, panel F, the levels of
expression varied considerably among the tumor cells in any one
glioblastoma biopsy as well as among the biopsies from different
patients. FIP200 also was detectable in an occasional glial cell in
19 of the 21 glioblastoma biopsy samples (data not shown). In the
tumor cells in the glioblastoma biopsies, the FIP200 staining
usually was located in the cytoplasm but occasionally was seen in
the nucleus, which is consistent with the staining patterns
described for FIP200 expression in breast cancer biopsies [26].
In the glial cells it was localized in the cytoplasm. Similar results
were obtained on immunohistochemical analysis of 15 additional
frozen biopsies (Fig. 1G). FIP200 staining of tumor cells was
observed in 14 of these biopsies, and in an occasional glial cell in
all of them. The reactivity of the rabbit antibody with FIP200 in
the brain biopsies was confirmed by immunoblotting detergent
lysates of 17 glioblastoma and five anaplastic astrocytoma, as well
as nine normal brain cortex or white matter biopsies (Figure S1
and data not shown). Immunoblotting of U-87MG and SNB19
human glioblastoma cells and 827 and 905 human glioblastoma
stem cells propagated as neurospheres with the rabbit antibody
showed that these cell lines express FIP200 (Figure S2A).
On examining the gliobastoma biopsies, we observed apparent
staining of FIP200 in the endothelial cells of the tumor-associated
blood vessels although such staining had not been noted on
examination of the normal brain samples. We therefore assessed
FIP200 staining in the vessels using a semi-quantitative immuno-
histochemical approach. The pathological identification of the
vessels was confirmed by staining of the von Willebrand factor
(vWf) in the endothelial cells in the adjacent sections and only
small and medium sized vessels were counted in case the FIP200
staining reflected differences in the size of the vessels. The tumor-
associated vessels exhibited the histologic abnormalities described
previously [27], i.e., dilated, tortuous, and with reduced pericyte
coverage. FIP200 was not detectable in the endothelial cells in the
small and medium-sized vessels in 19 of the 20 normal brain
biopsies (Figures 1B–D). (In the one biopsy in which staining of the
endothelial cells in the vessels was observed, approximately 5% of
the blood vessels contained endothelial cells that stained weakly for
FIP200.) In marked contrast, FIP200 was detectable in the
endothelial cells of the tumor-associated vessels in 16 of the 21
formalin-fixed, paraffin-embedded glioblastoma biopsies and in 14
of the 15 additional frozen biopsies (Fig. 1F–H). (In the five
formalin-fixed, paraffin-embedded biopsies in which the endothe-
lial cells in the tumor-associated vessels did not stain for FIP200,
the tumor cells also were negative for FIP200 and in the one
frozen biopsy that was negative for staining of the endothelial cells,
only 10% of the tumor cells were positive for staining of FIP200.)
This unexpected difference in expression of FIP200 in the
endothelial cells in the glioblastoma tumors and normal brain
was significant (p value,0.0001, Fisher exact test). Immunoblot
analysis of cultured primary normal human brain endothelial cells
propagated in complete media, which are commonly used as a
surrogate model for the endothelial cells in brain tumor-associated
microvessels, indicated that the rabbit antibody was reacting with
FIP200 in Glioblastoma Tumors
PLoS ONE | www.plosone.org 2 May 2011 | Volume 6 | Issue 5 | e19629Figure 1. FIP200 is expressed in tumor-associated endothelial cells as well as tumor cells in glioblastoma tumor biopsies. Formalin-
fixed and paraffin-embedded sections of surgical biopsies of normal brain (n=20) and glioblastomas (n=21), as well as frozen sections of
glioblastoma (n=15) were subjected to immunohistochemical analysis using diaminobenzidene as the substrate and counterstaining with
hematoxylin. The sections were reacted with a commercial rabbit anti-FIP200 (0.2 microgram/ml) or rabbit IgG (0.2 microgram/ml) for 24 h (4uC). A–
D, representative photomicrographs of sections of normal brain reacted with control rabbit IgG (A) or rabbit anti-FIP200 (B–D). Open arrowheads,
neurons; open arrows, unstained endothelial cells. Magnification=4006. E–H, representative photomicrographs of glioblastoma tumor sections
reacted with 0.2 microgram/ml control rabbit IgG (E) or rabbit anti-FIP200. F–G, representative micrographs of sections of glioblastoma tumors in
FIP200 in Glioblastoma Tumors
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tumor-associated vessels in the glioblastoma tumor biopsies, the
FIP200 staining was cytoplasmic.
FIP200 Downregulation Inhibits Proliferation and Induces
Apoptosis of Glioblastoma Cells, Immortalized
Astrocytes, and Cultured Primary Human Brain MvEC
Two duplex oligonucleotides (FIP200 siRNA #1 and #2) were
used to determine the effects of downregulation of endogenous
FIP200 protein on proliferation and apoptosis in the three cell types
found in glioblastomas. The U-87MGcell line was selected for these
studies as it expressed intermediate levels of FIP200 as compared to
the other cell lines tested (Figure S2A), immortalized human
astrocytes (E6/E7 cells) were used as a model for the tumor-
associated glial cells [28], and cultured human brain microvessel
endothelial cells were used as a model for the endothelial cells in the
tumor-associated vessels [29,30]. All experiments were carried out
using cells propagated in complete media. Transfection of all three
cell types with either of the two duplex oligonucleotides used in the
experiments effectively downregulated FIP200 protein as assessed
by densitometric analysis of immunoblots (Table S1). Controls
included a random scrambled siRNA or siFIP200 #1 and #2
duplex oligonucleotides with one or two base pair mutations
(mutant siFIP200).
Treatment of the U-87MG cells with either siFIP200 #1o r
siFIP200 #2 resulted in significant inhibition of proliferation as
compared to treatment with the random scrambled siRNA
(Figure 2A) or the mutant siFIP200 #1 and #2 RNAs
(Figure 2B). There also was significant inhibition of proliferation
when the cells were plated at a higher confluency prior to
transfection with siFIP200 #1o r#2 for 7 days (data not shown).
Downregulation of FIP200 by treatment of the immortalized
human astrocytes (E6/E7 cells) (Figure 2C) and the cultured
primary normal human brain endothelial cells (Figure 2D) also
resulted in a significant reduction in proliferation.
Transfection of all three cell types with either siFIP200 #1o r#2
for96 hinducedcaspase-7 cleavage(Figure3A)with higherlevelsof
caspase-7 cleavage occurring at day 7 (data not shown). Increased
caspase-7 cleavage was observed in the primary and the
immortalized human astrocytes on siFIP200 #1o r#2 treatment
for 96 h. Similarly, transfection of all three cell types with
siFIP200#1o r#2 for 96 h resulted in significantly higher numbers
of TUNEL-positive cells than transfection with the mutant siFIP200
#1o r#2 RNAs (Figures 3B & 3C, and data not shown).
FIP200 Downregulation Increases Pyk2 Activity, but not
FAK activity, in Glioblastoma Cells, Immortalized
Astrocytes, and Primary Human Brain MvEC
Somewhat surprisingly, we found that FIP200 downregulation in
U-87MG cells, E6/E7 immortalized astrocytes, and primary
human brain MvEC propagated in complete media did not affect
either the levels of FAK activity (as determined by the level of
autophosphorylation at Y397) or the levels of FAK protein
(Figures 4A & 4B). In contrast, downregulation of FIP200 enhanced
the activity of Pyk2 in all three cell types although it did not enhance
the levels of Pyk2 protein (Figures 4C and 5). The levels of
autophosphorylation on Y402 relative to normalized Pyk2 protein
were approximately 2-fold higher in the U-87MG cells and the
primary human brain MvEC, and 4-fold higher in the E6/E7 cells
at 48h after knockdown of FIP200. At the same time-point, the
levels of autophosphorylation were approximately 4-fold higher in
U-87MG cells propagated in suspension (data not shown).
As the Pyk2 autophosphorylation site has been shown to be
necessary for the pro-apoptotic effect of Pyk2 [11,18], we
investigated whether a TAT-Pyk2 fusion protein containing the
autophosphorylation site (abbreviated TAT-Pyk2-AP) [31] could
block the pro-apoptotic effect of downregulation of FIP200. A
TAT-Pyk2 fusion protein containing the Grb2 binding site (Y881)
was used as a control [31]. The TAT-Pyk2-AP fusion protein
(150 nM) significantly reduced the pro-apoptotic effect of
downregulation of FIP200 in both the U-87MG glioblastoma
cells (Figure 6A) and the primary human brain MvEC (Figure 6B).
These data suggest that the apoptosis associated with the
downregulation of FIP200 protein in the U-87MG cells and
primary brain MvECs propagated in complete media most likely
requires activation of Pyk2.
FIP200 also has been shown to promote the activity of S6 kinase
by associating with and inhibiting the function of the TSC1&2
complex of proteins [32]. To determine the effects of FIP200
downregulation on S6 kinase activity, the cell lysates were blotted
for phospho-p70 S6 kinase (Thr389). We found a small reduction
(<30% based on densitometry when normalized to the loading
control cortactin) in S6 kinase activity on FIP200 downregulation
in the U-87MG cells at 96 h (data not shown), suggesting that a
reduction in S6 kinase activity may contribute in part to the
decreased proliferation we observed on FIP200 downregulation.
Greater Amounts of FIP200 Protein are Co-
Immunoprecipitated with Pyk2 than with FAK
Immunoprecipitation of Pyk2 from lysates of U-87MG cells,
resulted in co-immunoprecipitation of FIP200 (Figure 7A, lane 1)
and downregulation of FIP200 by treatment of the cells with
siFIP200 reduced the 200-kDa band detected in the Pyk2
immunoprecipitate by an estimated 70% (based on densitometry)
(Figure 7A, lane 2). Immunoprecipitation of FAK from lysates of
U-87MG cells did not result in detectable coprecipitation of
FIP200 (Figure 7B) even after prolonged exposure of the
autoradiographs (data not shown). Thus, there is an apparent
preferential association of FIP200 with Pyk2 in these cells.
In contrast, FIP200 co-immunoprecipitated with both Pyk2 and
FAK from lysates of the primary human brain MvEC (Figure 7C,
lane 1, and Figure 7D, lane 1, respectively), although lesser
amounts of FIP200 were associated with FAK than Pyk2.
Treatment of the cells with siFIP200 reduced the 200-kDa band
associated with Pyk2 (Figure 7C, lane 2) and with FAK (Figure 7D,
lane 2) by an estimated 70% and 60% respectively (based on
densitometric analysis). The FIP200 downregulation increased
Pyk2 activity (pPyk2(Y402) blot) (Figure 7C, lane 2), but not FAK
activity (pFAK(Y397) blot) (Figure 7D, lane 2) in the MvEC used
in this assay. Thus, there also is an apparent preferential
association of FIP200 with Pyk2 in the MvEC. The levels of total
Pyk2 protein and total FAK protein in the U-87MG and MvEC
cell lysates are shown in Figure 7E.
A Reduction in the Association of Fyn with FAK Occurs
on FIP200 Downregulation
Activated Pyk2 may compete with FAK for binding partners
and thereby decrease the FAK-promoted pro-survival signal in
which tumor cells expressed FIP200 (28 of 36). Filled arrow-head, tumor cell expressing FIP200; filled arrows, endothelial cells expressing FIP200.
Sections were viewed and photographed using a Leica DM4000 microscope. Magnification, 4006.
doi:10.1371/journal.pone.0019629.g001
FIP200 in Glioblastoma Tumors
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associated with a reduction in the amounts of cellular Src or Fyn
associated with FAK in other cell types [11,13]. As we have shown
previously that Fyn, Lyn and c-Src are the predominant Src family
members that are expressed in glioblastoma tumors and in the U-
87MG cell line [33,34], we examined the effects of FIP200
downregulation on the association of these molecules with FAK.
We found that FIP200 downregulation reduced the amount of Fyn
associated with FAK in the U-87MG cells (60% decrease by
normalized densitometry) (Figure 7F), but did not reduce the
association of Lyn or c-Src with FAK (data not shown). Similarly,
in the human brain MvEC, we found a reduction in the amount of
Fyn (25% decrease) associated with FAK on FIP200 downregu-
lation, and no decrease in Lyn or c-Src association with FAK (data
not shown). Thus, one possible explanation for the observed effects
on FIP200 downregulation is that pPyk2 is competing with FAK
for Src family binding partners, but we have not ruled out other
possible explanations.
FIP200 and Pyk2 Localization is Largely Cytoplasmic and
Diffuse
On analysis of the cellular distribution of FIP200 using double-
label immunofluorescence, we found that the expression was
largely cytoplasmic and diffuse in the U-87MG cells and primary
human brain MvEC (Figures S3A & S3C, arrows) as reported
previously in other cell types [13]. We did not observe localization
of FIP200 to focal adhesions. Similar to FIP200, we found that
total Pyk2 localization was cytoplasmic and diffuse (Figures S3A–
D), independent of FIP200 downregulation and consistent with
that reported previously in fibroblasts and PC12 cells [13,35].
Figure 2. Cell proliferation is inhibited in glioblastoma cells, immortalized astrocytes, and primary human brain MvECs on
downregulation of FIP200. U-87MG human glioblastoma cells (A & B) and E6/E7 immortalized human astrocytes (C) were plated in complete
media (1610
4 cells/well) in replicas of three or four (20 h) then treated with siFIP200 #1 or siFIP200 #2, or with non-silencing siRNA (denoted as
liposome) or with mutant siFIP200 #1 or mutant siFIP200 #2 for the indicated time periods with the cell media and siRNA being replaced every three
to four days. The cells were harvested and adherent cells counted. (D) Primary human brain MvEC, which are a surrogate model of tumor-associated
MvECs and express FIP200, were plated in complete media (10% FBS, 10 ng/ml VEGF, 5 ng/ml bFGF) and treated with siFIP200 #1o r#2 or with
mutant siFIP200 #1o r#2 and the adherent cells counted. The means 6 S.E.M were calculated and the data are plotted as the percentage of
proliferation (cell number) relative to control cells. The experiment was repeated 26 and representative results are shown. (* probability=0.03;
** probability #0.01 as compared to the control at that day; unpaired t test.)
doi:10.1371/journal.pone.0019629.g002
FIP200 in Glioblastoma Tumors
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Pyk2. As expected, FAK protein largely co-localized with vinculin
to focal adhesions in both cell types, independent of FIP200
downregulation (data not shown).
Analysis of the cellular localization of these proteins in four
frozen glioblastoma biopsy samples by triple-label immunofluo-
rescence indicated cytoplasmic co-expression of FIP200 and Pyk2
in endothelial cells in tumor-associated blood vessels identified by
Figure 3. Apoptotic cell death is induced in glioblastoma cells, astrocytes, and primary human brain MvECs on downregulation of
FIP200. A, Human astrocytes, U-87MG glioblastoma cells and human brain MvEC (HBMvEC) were plated in complete media (20 h) and then treated
with FIP200 siRNA, a non-silencing control siRNA (control #1), or mutant siFIP200 (control #2) for 96 h. Whole cell lysates were resolved on disulfide-
reduced 12% SDS-PAGE and blotted with the indicated antibodies as described in the Materials and Methods. The experiment was repeated 26with
the three different cell types and a representative experiment is shown. B & C, U-87MG and E6/E7 E6/E7 immortalized astrocytes were plated in
replicas of two, treated with siFIP200 or mutant siFIP200 as described for Panel A for 96 h and then subjected to the TUNEL assay. TUNEL-positive
cells were counted in 10 fields per well in a blinded manner and the data analyzed and presented as the mean 6 S.E.M. Highly similar results were
seen with HBMvEC plated and treated as above with siFIP200 and then subjected to TUNEL assay at 96 h. The experiment was repeated 26and a
representative result is shown.
doi:10.1371/journal.pone.0019629.g003
FIP200 in Glioblastoma Tumors
PLoS ONE | www.plosone.org 6 May 2011 | Volume 6 | Issue 5 | e19629Figure 4. Downregulation of FIP200 protein with siRNA enhances Pyk2 activity without affecting FAK activity in gliobastoma cells
and E6/E7 immortalized astrocytes. A, B, U-87MG glioblastoma cells and immortalized human astrocytes were plated in complete media (10%
FBS), treated with 20 nM FIP200 siRNA (#1, or #2) or control non-silencing siRNA for the indicated times, detergent lysed, equivalent amount of
lysate resolved on disulfide-reduced 6% SDS-PAGE, and then blotted with the indicated antibodies. C, U-87MG glioblastoma cells and immortalized
human astrocytes were plated in complete media (10% FBS), and treated with different concentrations of FIP200 siRNA (#1, or #2) or control non-
silencing siRNA for 53 h, detergent lysed, equivalent amount of lysate resolved on disulfide-reduced 6% SDS-PAGE, and then blotted with the
indicated antibodies. In Panel C all lanes are from the same gel and the densitometric ratio of pPyk2/normalized Pyk2 was set at 1.0 for the cells
treated with control non-silencing siRNA, and the ratio for the cells treated with siFIP200 expressed relative to the ratio for the cells treated with
control non-silencing siRNA. The experiments were repeated 26and representative blots are shown.
doi:10.1371/journal.pone.0019629.g004
FIP200 in Glioblastoma Tumors
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are localized in a manner that is consistent with their potential
association. In the tumor cell compartment of all samples, we
found cytoplasmic co-expression of FIP200 and Pyk2 in some
tumor cells (Figure 8B), also suggesting that FIP200 and Pyk2 are
localized in a manner that is consistent with potential association.
Nuclear localization of FIP200 also was observed in some tumor
cells (data not shown). The cytoplasmic localization of Pyk2 in the
tumor-associated endothelial cells and in the tumor cells in frozen
glioblastoma biopsies is consistent with the report of another group
that examined Pyk2 expression in glioblastoma biopsies [36].
Discussion
Our demonstration that specific downregulation of endogenous
FIP200 protein can increase Pyk2 activity and induce apoptosis
adds to the body of evidence that FIP200 can regulate Pyk2 and
underscores the importance of FIP200 in the regulation of cell
survival. Collectively, our results indicate that FIP200 regulation of
Pyk2 can play an important role in the survival of glioblastoma
tumor cells and suggests the intriguing possibility that this
mechanism may contribute to sustained tumor growth by
promoting not only the survival of tumor cells but also the intra-
tumor glial cells and the tumor-associated endothelial cells.
These results underscore the importance of FIP200 in the
regulation of cell survival in that they demonstrate that
downregulation of FIP200 can induce apoptosis. The potential
role of pPyk2 in promoting the apoptosis induced by FIP200
downregulation was indicated by the ability of a TAT-Pyk2 fusion
protein containing the autophosphorylation site to inhibit the pro-
apoptotic effect, whereas a TAT-Pyk2 fusion protein containing
the potential Grb2 binding site (Y881) did not. This is consistent
with the prior report that the N-terminus and the kinase domains
of Pyk2, but not the C-terminus, are necessary for the pro-
apoptotic effect of Pyk2 [11]. Several other mechanisms have been
implicated in FIP200 regulation of apoptosis in other cell types. In
the FIP200-null mouse embryos, no changes in Pyk2 activity were
detected in the hepatocytes or cardiomyocytes and the enhanced
apoptosis was attributed to a decrease in S6 kinase activity [5].
The TSC1&2 complex is thought to negatively regulate cell
proliferation through S6 kinase, mTOR, and 4E-BP1 [5,32]. On
analysis of the p70 S6 kinase activity in the glioblastoma cells we
did find that there was a slight reduction (an estimated 30%) in this
Figure 5. Downregulation of FIP200 protein with siRNA
enhances Pyk2 activity without affecting FAK activity in
primary human brain MvEC. A–C, Primary human brain MvEC were
plated in complete media (10% FSB) and treated with siFIP200 #1, #2,
or #4, or with control liposomes or mutant siFIP200 #1 for 96 h,
detergent lysed, the lysate resolved on disulfide-reduced 7.5% SDS-
PAGE and blotted with the indicated antibodies. In Panel C, the
densitometric ratio of pPyk2/normalized to Pyk2 was set at 1.0 for the
cells treated with mutant siFIP200, and the ratio for the cells treated
with specific siFIP200 expressed relative to the ratio for the cells treated
with mutant siFIP200. The experiment was repeated and representative
blots are shown.
doi:10.1371/journal.pone.0019629.g005
Figure 6. A TAT-Pyk2 fusion protein containing the autopho-
sphorylation site inhibits the pro-apoptotic effect observed
with the downregulation of FIP200-protein. (A) U-87MG glioblas-
toma cells plated in complete media (10% FBS) (20 h) were treated with
the indicated siRNA for 48 h, the media removed and the cell
monolayer treated with 150 nM TAT-Pyk2 fusion protein containing
the autophosphorylation site (AP) or the potential Grb2 binding site
(Grb2) for 1 h, followed by fresh media and siRNA for 38 h, detergent
lysis, and immunoblotting with the indicated antibodies. B, Human
brain MvEC (HBMvEC) were plated in complete media (20 h), treated
with the indicated siRNA (50 h), the media removed and the cell
monolayer treated with 75 nM TAT-Pyk2-fusion protein (1 h), followed
by fresh media and siRNA for 36 h, detergent lysis and immunoblotting
with the indicated antibodies. The experiment was repeated and
representative blots are shown.
doi:10.1371/journal.pone.0019629.g006
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kinase activity could contribute to the inhibition of proliferation we
observed on FIP200 downregulation but the current results suggest
that the mechanism by which FIP200 regulates apoptosis in
glioblastoma tumor cells and brain MvECs differs from that in the
embryonic murine cardiocytes and hepatocytes in that it requires
Pyk2 activity. It also has been reported that FIP200 upregulates
the expression of the retinoblastoma (Rb) gene [26,37], thus the
downregulation of endogenous FIP200 protein in our cells could
potentially inhibit cell proliferation by decreasing the Rb gene
expression. Although the association of FAK with the death
domain kinase receptor interacting protein (RIP) is thought to
prevent the pro-apoptotic signal of RIP [38], we could not detect
an association of FAK with RIP in the U-87MG cells by co-
immunoprecipitation (D. Wang and C.L. Gladson unpublished
observation).
Although both Pyk2 and FAK were expressed in the glio-
blastoma cells and human brain MvEC, we found that FIP200
Figure 7. FIP200 protein predominantly associates with Pyk2 in the glioblastoma cells and primary human brain MvEC. A–D, U-87MG
glioblastoma cells (A&B) and primary human brain MvEC (C&D) were plated in complete media for 20 h, treated with siFIP200 or mutant siFIP200 for
96 h, detergent lysed, and immunoprecipitated with the indicated antibody. The immunoprecipitates were subjected to 7.5% disulfide-reduced SDS-
PAGE and immunoblotted with the indicated antibodies, as described in the Materials and Methods. Panels A & B are from the same gel. (E) U-87MG
cells and human brain MvEC plated in complete media were detergent lysed, subjected to 8% SDS PAGE, and immunoblotted with the indicated
antibodies. (F) U-87MG cells and human brain MvEC plated as above and treated with the indicated siRNA for 72 h were detergent lysed,
immunoprecipitated with anti-FAK antibody, the immunoprecipitate subjected to SDS-PAGE, followed by immunoblotting with the indicated
antibodies. The experiment was repeated 26and representative blots are shown.
doi:10.1371/journal.pone.0019629.g007
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FIP200 downregulation in the unmanipulated U-87MG glioblas-
toma and brain MvEC cells propagated in complete media. The
association of the endogenous FIP200 with Pyk2 in the lysates of
the unmanipulated glioblastoma cells and human brain MvEC
propagated in complete media suggests that the FIP200 regulation
of Pyk2 activity in these cells may be a direct effect. The
interaction of FIP200 with Pyk2 has been shown to inhibit Pyk2
activity in other cell types [2] and Pyk2 activation has been shown
to promote its dissociation from FIP200. Thus, it is possible that
downregulation of the endogenous FIP200 may lead to exposure
of the autophosphorylation site permitting autophosphorylation of
Pyk2 [2,13,39].
The activities of Pyk2 and FAK and their contribution to
specific cell functions, including apoptosis, are regulated in large
part by their shuttling between different compartments of the cell.
The largely cytoplasmic and diffuse pattern of FIP200 that we
observed on immunofluorescence analysis of both the U-87MG
cells and the primary human brain MvECs is consistent with the
pattern reported for fibroblasts [2,13]. The distribution of Pyk2
also was predominantly cytoplasmic and diffuse, which is
consistent with the preferential co-precipitation of FIP200 with
Pyk2 we observed, whereas FAK was largely localized to the focal
adhesions and FIP200 was not detectable at these sites. The
regulation of localization of FAK and Pyk2 to focal adhesions can
be independently influenced by the presence or absence of specific
binding partners, for example, gelsolin has been reported to bind
Pyk2 but not FAK [40] as well as differences in the affinity of FAK
and Pyk2 for shared binding partners within the focal adhesions,
such as paxillin [41–43]. FIP200 localization to the nucleus has
been reported in other cell types [26], emphasizing a potential role
for FIP200 in regulation of transcription through, for example, its
potential interaction with Rb, which is a regulator of transcription.
We did not observe a clear-cut association of FIP200 with the
nuclei of the U-87MG or primary human MvECs, but we did not
utilize biochemical assays to explore this possibility and cannot
rule out a partial nuclear localization. However, the pattern of
expression of FIP200 in the tumor cells in the glioblastoma
biopsies was heterogeneous. Although the pattern was predomi-
nantly cytoplasmic, nuclear staining was observed and partial
FIP200 localization to the nucleus was observed in tumor cells in
10 of 36 biopsy samples. In contrast, in the tumor-associated
Figure 8. Co-Expression of FIP200 and Pyk2 in the cytoplasm of tumor cells and of tumor-associated endothelial cells. Frozen
sections of four glioblastoma tumors were reacted with antibodies directed toward vWf (pink), FIP200 (green) and Pyk2 (red), followed by reaction
with Alexa 633-, Alexa 563- and Alexa 488-conjugated secondary antibodies, and DAPI staining, as described in the Materials and Methods. Images
were viewed and photographed on a Leica DMB microscope at 4006magnification. A1 & A2, triple-labeled tumor-associated endothelial cells; B,
double-labeled tumor cells; and C, secondary antibodies alone followed by DAPI staining. Merged images are shown at the reader’s far right.
doi:10.1371/journal.pone.0019629.g008
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FIP200 was largely cytoplasmic with only rare nuclear staining.
We observed a reduced association of Fyn with FAK on FIP200
downregulation in both U-87MG cells and the brain MvEC
although the levels of activity of FAK and its expression were
unaffected by the downregulation. This supports the concept that
activated Pyk2 competes with FAK for binding partners that affect
downstream signaling pathways, as shown in other cell types by
Zhao and colleagues [13]. Activated Pyk2 can signal the activation
of p38MAP kinase [20], a MAP kinase that can promote apoptosis
[44], and Pyk2 induction of apoptosis in cardiomyocytes requires
Src activation of p38MAP kinase [18]. FAK can promote cell
proliferation and cell survival through the activation of other MAP
kinase(s) in a cell-type and experimental context-dependent
manner reviewed in [3,45].
It should be emphasized that there was heterogeneity in the
levels of expression of FIP200 in the tumor cells and that FIP200
was not detectable in all of the tumor cells within a single biopsy
specimen. In addition, we did not detect FIP200 protein in tumor
cells in 8 of 36 of the glioblastoma biopsies, although FIP200 was
detected in scattered glial cells and the endothelial cells in the
tumor-associated vessels in 3 of these 8 tumors. Currently, it is not
known whether the failure to detect FIP200 protein in tumor cells
in eight of the glioblastoma biopsy samples is due to a gene
deletion in these cells or an environmentally triggered reduction in
the levels of FIP200 mRNA or protein.
The location of the FIP200 gene on chromosome 8q11 [6,8,9]
has led other investigators to formulate the hypothesis that FIP200
could be an ‘‘anti-tumor’’ or ‘‘tumor suppressor’’ gene. Recently,
however, Wei and colleagues [23] created a conditional knockout
of FIP200 in the MMTV-Cre model of breast cancer and showed
no promotion of tumorigenesis, suggesting that FIP200 inactiva-
tion alone does not promote tumor formation. In addition, a prior
report demonstrated that overexpression of FIP200 in breast
cancer cells resulted in an inhibition of both cell cycle progression
and clonogenic cell survival due to FIP200 promotion of p21
expression [7]. It is possible that the level of FIP200 protein in
cells, and the cell type, influences its function. For example, the
kinetics of FIP200 association with some of its binding partners,
such as Pyk2, FAK or the p21 or Rb promoter, could be altered
when FIP200 is overexpressed and this could be affected by the
experimental context and the specific cell-type. Taken together
with the expression of FIP200 in the tumor-associated endothelial
cells in the glioblastoma tumors but not the normal brain, these
data underscore the importance of elucidation of the factors that
regulate the expression of FIP200.
Materials and Methods
Reagents
The following antibodies were purchased, rabbit anti-FAK IgG
(Upstate Biotechnology, Cat# 06-543); mouse mAb anti-FAK
(Santa Cruz Biotechnology; clone # H-1); rabbit anti-phospho-
FAK (pY397) (Chemicon, Inc.); mouse mAb anti-Pyk2 (BD
Biosciences-Transduction Laboratories; clone 11); rabbit anti
Pyk2 (Santa Cruz, #SC9019), and rabbit anti-phospho-Pyk2
(pY402) (BioSource International and Upstate Biotechnology).
Two rabbit anti-FIP200 antibodies were used. One was purchased
from (ProteinTech, Chicago, IL) and the other, a rabbit anti-
FIP200 antibody directed toward the C-terminus, has been
described previously [2]. Mouse mAb anti-death domain kinase
receptor interacting protein (RIP) (BD Transduction Laborato-
ries); rabbit anti-cleaved caspases 7 (Calbiochem); mAb anti-actin
(Sigma), rabbit monoclonal anti-phospho-p70 S6 kinase (Thr389)
(Upstate Biotechnology), mAb anti-glyceraldehyde-3-phosphate-
dehydrogenase (GAPDH) (Fitzgerald Laboratories), mouse anti-a-
tubulin (GeneTex, DM1A) and rabbit antibodies toward Fyn, Lyn
and c-Src (Santa Cruz Biotechnology) also were purchased.
Control normal rabbit IgG and normal IgG were purchased from
Santa Cruz Biotechnology.
Cell culture
U-87MG human glioblastoma cells were obtained from the
ATCC and propagated as described [33]. Human astrocytes
immortalized with the telomerase gene and the E6 and E7 viral
genes have been characterized previously and were propagated as
described [28], and primary human astrocytes were purchased
from Cell Systems (Kirkland, WA) and propagated as recom-
mended. Highly similar results were found on FIP200 downreg-
ulation in both the immortalized and the primary human
astrocytes. SNB19 human glioblastoma cells were cultured as
described previously [46], and were a kind gift from Dr. Jasti Rao
(University of Illinois, Peoria, IL). The 827 and 905 human
glioblastoma stem cells were cultured as described previously [47].
Primary human brain MvEC were obtained from Cell Systems
and propagated as directed [29,30].
Human tissues
Frozen glioblastoma and anaplastic astrocytoma tumor tissue,
paraffin sections of glioblastoma tumor, and normal brain tissue
(tissue adjacent to seizure foci resected to gain access to the seizure
foci), were obtained from surgical samples with the approval of the
Institutional Review Board of the University of Alabama at
Birmingham (IRB number: X050415007) or the Cleveland Clinic
(IRB number: 2559). All tissue banked at the University of
Alabama at Birmingham and the Cleveland Clinic was with the
written consent from the patient. De-identified tissue was provided
by the tissue bank at the University of Alabama at Birmingham or
the Cleveland Clinic. Glioblastoma tumor (Grade IV of IV) and
anaplastic astrocytoma tumor (Grade III of IV) were diagnosed
according to the most recent World Health Organization
Classification of Tumors of the Central Nervous System [48].
Frozen tumor and normal brain tissues were lysed in RIPA lysis
buffer with protease inhibitors as described [34].
Immunohistochemistry
Paraffin and frozen sections (7 microns thick) were stained as
described previously [34] with the Avidin/Biotin Kit (Vector
Laboratories) as recommended. Rabbit anti-FIP200 was utilized at
0.2 mg/ml for paraffin sections and 1.13 mg/ml for frozen sections
as described previously [10], and the following antibodies mAb
anti-Pyk2, rabbit anti-vWf, goat anti-vWf, and the negative control
IgG were utilized at a 1:100 dilution of the stock. Sections were
viewed and photographed using a Leica DM4000B microscope.
Downregulation of FIP200 with siRNA
Three validated duplex siRNAs for FIP200 were purchased
from Qiagen (Valencia, CA): siFIP200 #1( C a t .# SI02664571),
target sequence CTGGGACGCATACAAATCCAA; siFIP200#2
(Cat #SI02664578), target sequence ACGCAAATCAGTTGAT-
GATTA; and siFIP200 #4( C a t#SI00108122). To further
substantiate specific downregulation of FIP200, siFIP200 #1a n d
#2 duplex oligonucleotides with one or two base pair mutations
(mutant siFIP200) were purchased from Qiagen and used as
controls. The target of the mutated siFIP200#1i sC T G G G A C G -
GATACAAATCCAA; and the target of mutated siFIP200
#2, ACGCAAGTCCGTTGATGATTA. Control non-silencing
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siRNA was carried out using the HiPerfect transfection reagent
(Qiagen), according to the manufacturer’s instructions, with empty
liposomes being used as a negative control. The efficiency of the
downregulation of FIP200 in the different cell types was confirmed
and monitored by western blot analysis. No effects on the
morphology of the cells were observed.
Immunoblot analysis
Immunoblotting was carried out as described previously [17].
The cells were lysed in the Cell Lytic-M reagent lysis buffer
(Sigma) or with 1% NP40 buffer with protease inhibitors [17].
Immunoblotting after lysis of the cells in RIPA lysis buffer yielded
similar results except that the blots were not as clean. The rabbit
anti-FIP200 antibody directed toward the C-terminus [2] was used
at a 1:1000 dilution and the commercial anti-FIP200 at
0.2 microgram/ml. Band intensities were measured by densitom-
etry and normalized to the intensity of the loading control, i.e.,
antibody directed to actin, a-tubulin or cortactin. FAK activity
was detected by blotting using an antibody specific for
pFAK(Y397), and then stripping and reprobing for total FAK
and a loading control. Pyk2 activity was detected by blotting using
an antibody specific for pPyk2(Y402), then stripping and reprobing
for total Pyk2 and a loading control. The activity of FAK and Pyk2
was determined by normalizing the intensity of the pFAK(Y397)
and pPyk2(Y402) bands to total FAK or Pyk2 bands, respectively.
Cell proliferation and apoptosis assays
Immortalized astrocytes, U-87MG cells, and human brain
MvEC were plated on 12- or 24-well plates in complete media
(10% FBS) and then treated with siRNA for the indicated times;
the medium was changed and fresh siRNA added every three or
four days. To assess proliferation, adherent cells were harvested
with trypsin/IEDTA, stained with trypan blue and viable cells
counted using a hematocytometer. The TUNEL apoptosis assay
was performed as described previously [29,30].
Immunoprecipitation
U-87MG cells or human brain MvEC were plated in complete
media at 80% confluence for 20 h, followed by siRNA treatment
for the indicated number of days. The cells were then lysed using
1% NP40 Lysis Buffer with protease inhibitors as described [33].
For immunoprecipitation analysis equivalent amount of protein
lysate (50 to 200 mg) from each sample was incubated with 5–
10 mg of the appropriate antibody followed by pull-down using
TrueBlot anti-rabbit IP beads (eBiosciences) overnight at 4uC. The
immunoprecipitates were washed 3 times with PTO buffer (PBS
with 0.1% ovalbumin and 0.5% Tween 20) and 3 times with PT
buffer (PBS with 0.5% Tween 20) and subjected to 7.5% disulfide-
reduced SDS-PAGE, transferred to PVDF membrane and
immunoblotted as described [33].
Immunofluorescence analysis
Cells were plated in complete media (10% FBS) and treated
with siRNA for the indicated times. Frozen tissue was sectioned at
7 microns. Immunofluorescence was performed as described
previously [49]. A Leica DMF microscope was used for viewing
and photomicrographs were obtained using a 406oil objective.
TAT-Pyk2 Fusion Proteins
The following constructs in the pTatHA bacterial expression
vector were provided by Dr. Carl Nathan (Weil Medical College
of Cornell University, NY): nt 1102–1557, coding for amino acids
365–518 and containing the autophosphorylation site (abbreviated
AP), nt 1741–2099, coding for amino acids 581–700 and
containing the putative phosphatidyl inositol 39 phosphate (PI3)
kinase binding domain (abbreviated PBM); and nt 2617–2986,
coding for amino acids 873–995 and containing the Grb2 binding
site (abbreviated Grb2BS) [31]. The constructs were grown in
BL21 DE3 E. coli, and the recombinant proteins purified as
described [31]. TAT fusion proteins were used for these studies as
they have been shown to transduce nearly 100% of mammalian
cells regardless of cell type [50,51]. Both the TAT-Pyk2 fusion
proteins are well characterized and do not exhibit toxicity in
various in vitro and in vivo models [31,51].
Supporting Information
Figure S1 FIP200 expression in glioblastoma tumor and
normal brain biopsies. Tissues were detergent lysed and
200 micrograms of each sample electrophoresed on an 6%
disulfide-reduced SDS-PAGE, transferred to Immobilon mem-
brane, and then immunoblotted with the indicated antibodies, as
described in the Materials and Methods. The densitometirc
reading for the FIP200 band in each sample was normalized to the
actin band that served as a loading control.
(TIF)
Figure S2 FIP200 expression in glioblastoma cells and
primary brain microvessel endothelial cells (MvEC). U-
87MG and SNB19 human glioblastoma cells plated as a
monolayer in complete media (A), 905 and 827 human
glioblastoma stem cells propagated as neurospheres in serum-free
media (A), as well as primary human brain MvEC plated as a
monolayer in complete media (B), were detergent lysed, equivalent
amount of lysate subjected to 7.5% SDS-PAGE, and the gels
immunoblotted with the indicated antibodies as described in the
Materials and Methods. The experiment was repeated and
representative blots are shown.
(TIF)
Figure S3 FIP200 and Pyk2 are localized in a cytoplas-
mic, diffuse manner in glioblastoma cells and human
brain MvEC. U-87MG glioblastoma cells or primary human
brain MvEC were plated onto chamberslides in complete media
(10% FBS) or in complete media with 10 ng/ml VEGF, and 5 ng/
ml bFGF, respectively, for 20 h, treated with siFIP200 or mutant
siFIP200 (labeled control siRNA) for 48 h, fixed, and subjected to
double-label immunofluorescence, as described in the Materials
and Methods. MAb anti-vinculin was detected with Alexa 488-
conjugated anti-mouse antibody (green fluorescence), and rabbit
anti-FIP200, and anti-total Pyk2 antibodies were detected with
anti-rabbit Alexa 594-conjugated antibody (red fluorescence).
Merged images are shown. Arrows denote a diffuse cytoplasmic
localization (FIP200 and Pyk2), and arrowheads denote a
localization at focal adhesions (vinculin). Cells were viewed and
photographed using a Leica DMR microscope. All panels,
magnification 4006. The experiment was repeated and represen-
tative photomicrographs are shown.
(TIF)
Table S1 FIP200 protein expression in cells treated with
siFIP200. The cells were propagated in complete media and
treated with siFIP200 #1o r#2 at 20 nM, empty liposomes or
mutant siFIP200 as described in the Materials and Methods
section for the indicated time periods. The cells were then
harvested and FIP200 protein expression evaluated by western
blotting. Densitometric readings of the FIP200 band on the blots
were normalized to the loading control protein (actin, GAPDH or
FIP200 in Glioblastoma Tumors
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siFIP200-treated cells is shown as a percentage of the normalized
FIP200 expression in the control cells treated with *liposome or
+mutant siFIP200. Abbreviations: HBMvEC, primary human
brain microvessel endothelial cells.
(TIF)
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